Nomos takes ultrasound-guided radiation therapy to China
This article was originally published in Clinica
North American Scientific's radiation oncology division, Nomos, has received approval in China to market its ultrasound system for viewing cancerous tumors prior to the delivery of radiation therapy. The image-guided radiation therapy (IGRT) system, called BAT Sxi, is designed to be compatible with all linear accelerators and most treatment planning products, said the Chatsworth, California firm. Noting that it had gained Chinese market go-ahead for its Peacock intensity-modulated radiation therapy (IMRT) product in September 2005, the company said it remained hopeful that it would have its full range of products available in China during fiscal 2006. The firm is also in the process of registering in China its Prospera I-125 brachytherapy seeds for treating prostate cancer.
You may also be interested in...
With an eye toward addressing uncertainty as to whether patents that cover drug products’ device components or risk management elements should be listed, the agency seeks input on the need for additional clarity around the types of patents that must be submitted and the impact of any change in listing practices on drug development.
Mylan and Lupin have revealed when they expect to launch their etanercept biosimilar, Nepexto, in Europe after receiving formal European Commission approval.
The sellers of the anti-aging “cure-all” reached an agreement with the FTC in February that prohibits them from making false and unsubstantiated health claims and requires them to pay $660,000 in total to the Commission. Refund checks now are being issued to more than 1,300 defrauded consumers.